Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 11/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29455253 | 0.89 | HDAC6 (0.45) | KIF11RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL975668 | 0.88 | KIF11 (0.46) | KIF11HPGDRAB9ANPC1SIRT2 | |
| SCHEMBL22468869 | 0.87 | KIF11 (0.57) | KIF11 | |
| SCHEMBL11885305 | 0.87 | KIF11 (0.45) | KIF11HPGDRAB9AMEN1KMT2A | |
| SCHEMBL3158110 | 0.87 | HDAC3 (0.46) | KIF11HPGDRAB9AMEN1KMT2A | |
| SCHEMBL1389497 | 0.83 | KIF11 (0.47) | KIF11HPGDRAB9ANPC1SIRT2 | |
| SCHEMBL8499003 | 0.82 | KIF11 (0.54) | KIF11HPGD | |
| SCHEMBL5965491 | 0.81 | SIRT2 (0.44) | KIF11HPGDRAB9ANPC1SIRT2 | |
| SCHEMBL7732927 | 0.81 | KIF11 (0.45) | KIF11HPGDRAB9ANPC1SIRT2 | |
| SCHEMBL7734314 | 0.81 | HPGD (0.55) | KIF11HPGDRAB9ANPC1SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250127797-A1 | PRODRUG COMPRISING A DRUG-LINKER CONJUGATE | ASCENDIS PHARMA A/S (DK) | 2025-04-24 | — | — | US | disclosed |
| US-20240041897-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | ASCENDIS PHARMA GMBH (DE) | 2024-02-08 | — | — | US | disclosed |
| US-20220331334-A1 | Prodrug Comprising a Drug-Linker Conjugate | ASCENDIS PHARMA A/S (DK) | 2022-10-20 | — | — | US | disclosed |
| EP-3981761-A2 | INTERMEDIATES FOR PRODRUGS | Ascendis Pharma A/S (DK) | 2022-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240041897-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | H1-0, H1-3, H1-2 | KIF11 3253/4885HPGD 1998/4885RAB9A 1928/4885 |
| US-20220331334-A1 | Prodrug Comprising a Drug-Linker Conjugate | H1-0, H1-3, DLST | KIF11 3239/4885HPGD 1728/4885RAB9A 1957/4885 |
| US-20250127797-A1 | PRODRUG COMPRISING A DRUG-LINKER CONJUGATE | H1-0, H1-3, DLST | KIF11 3239/4885HPGD 1728/4885RAB9A 1957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.